Background {#Sec1}
==========

Multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) have emerged as significant public health threats and pose a significant risk to the control of tuberculosis (TB) worldwide \[[@CR1]\]. Globally, an estimated 3.3 % of new TB cases and 20 % of previously treated cases become multidrug resistant \[[@CR1]\]. In 2014, there were about 480,000 new cases of MDR-TB worldwide and approximately 190,000 deaths from the disease. An estimated 9.7 % of people with MDR-TB have XDR-TB \[[@CR1]\].

Treatment for drug resistant TB patients has focused on hospital and ambulatory based management \[[@CR2]--[@CR4]\]. The rationale for this has been to monitor complex drug regimens, optimize adherence, and limit community transmission \[[@CR5]\]. Centralized interventions can be advantageous, as they concentrate on MDR-TB cases from larger regions and allow for management by trained experts in low-prevalence settings \[[@CR6]\]. Despite the effectiveness of centralized interventions, hospital and ambulatory based management have limitations such as the need for monthly follow up visits, increased economic and social costs involved in keeping patients isolated in hospitals and long waiting lists of TB patients needing treatment \[[@CR7]--[@CR10]\]. Additionally, inadequate human resources to deliver treatment and care, insufficient bed capacity to hospitalize all new patients, and the difficulty in retaining and monitoring patients on discharge at the end of the intensive phase \[[@CR7]--[@CR10]\] have contributed to poor treatment success rates and increasing lost to follow up. Due to limited healthcare resources and long-term treatment regimens, community-based treatment has been utilized as an alternative care model to hospital-based treatment \[[@CR10]--[@CR12]\].

Community-based management of MDR-TB incorporates two key strategies: decentralization of hospital care from a distant specialist unit to a local district hospital and early discharge of MDR-TB patients into the community. Decentralization is achieved by the development of infrastructure for in-patient care at a district level hospital and skills transfer from the specialist referral unit \[[@CR13]\]. Several studies \[[@CR5], [@CR6], [@CR14]\] have utilized a mix of interventions for community management of drug resistant tuberculosis (DR-TB) treatment, which includes utilization of family members and healthcare workers to administer DOTS-Plus, social assistance, support groups, routine home visits, and clinician support at the community-based sites.

Findings from several studies \[[@CR10], [@CR15]--[@CR17]\] suggest the impact of community-based treatment to be more effective than care in a traditional hospitalization setting, grounded on improved treatment success rate, lower lost to follow up, and shorter time to treatment initiation. Also, community-based treatment has been shown to increase access to care by improving access to diagnostic and treatment services to further strengthen treatment success rate \[[@CR10]--[@CR12]\]. The delivery of community-based TB treatment through community health workers has further improved access and service utilization of healthcare \[[@CR10]--[@CR12]\]. Thus, community-based treatment has facilitated access to treatment by making treatment closer to patient's home, and enhancing support to patients and their families. Community-based management of MDR-TB is considered vital and cost effective \[[@CR18]\] especially in low resource settings.

So far, only one meta-analysis has focused on comparing community-based treatment to hospitalized treatment for DR-TB \[[@CR19]\]. Although, another study (not a meta-analysis) has compared treatment outcomes in community-based care versus centralized hospitalization in South Africa \[[@CR15]\], however, more evidence is required in determining the influence of community-based treatment in bringing about increased treatment success rate. We carried out a systematic review and meta-analysis to compare the effectiveness of community-based management to traditional hospitalization in the care of patients with MDR-TB and XDR-TB patients in the 27 MDR-TB HBC.

Methods {#Sec2}
=======

Search strategy and selection criteria {#Sec3}
--------------------------------------

We searched PubMed, Cochrane, Lancet, and Centre for Reviews and Dissemination (CRD), Web of Science, and the International Journal of Tuberculosis and Lung Disease for studies published from January 2005 to October 2015. Searches were done from September 1, 2015 to October 31, 2015. The search included MeSH terms for MDR-TB and XDR-TB, "community DOTS-Plus" or "community health services" or "decentralized" or "home based care" and "hospitalization" or "centralized" or "in patient".

We included retrospective cohorts, prospective countries, and a case control study implementing community-based and hospitalized treatment in MDR-TB and XDR-TB patients aged \>18 years in the 27 MDR-TB HBC. Studies were included if they were published in English language, had at least ten patients in each study group, and patients were treated for a minimum of six months. For authors having more than one article on the topic, the most recent article was accepted or if the content was found different after review, then the other studies were also accepted. Studies were excluded if the study design was cross sectional or qualitative or did not report data that were useful for extraction. Studies with a sample size \< 10, active TB cases, utilized surgical interventions, and exclusively used first line therapy in their treatment protocol were also excluded.

Studies were considered community-based if the model of care was implemented in a decentralized setting, utilized family members, and local healthcare workers to directly observe treatment. For traditional hospitalization, our selection criteria included implementation in a centralized setting, and treatment requiring hospitalizations or frequent visits to a healthcare facility.

Screening and data extraction {#Sec4}
-----------------------------

Titles and abstracts of all articles were screened and retrieved by AOW and MO to identify potentially eligible studies. AOW and MO reviewed the full text of potentially eligible articles. These were evaluated using the inclusion and exclusion criteria. Database search results were imported into PubMed Bibliography, ProQuest Flow, and duplicate records were removed. Reasons for the exclusion of studies are documented and presented in Fig. [1](#Fig1){ref-type="fig"}. Information on the study characteristics and the primary treatment outcome of interest (treatment success rate or treatment failure rate) was extracted into Systematic Review Data Repository (SRDR) tool. Additionally, information on relevant treatment characteristics (adverse rate, default rate, regimen model, regimen duration, location, and provider) was extracted. These outcomes were only extracted when provided in studies.Fig. 1PRISMA Study flowchart

Treatment failure rate was defined as the proportion of patients that failed MDR-TB or XDR-TB treatment, whereas treatment success rate was defined as the proportion of patients that completed MDR-TB or XDR-TB treatment and cured. Adverse rate was defined as the proportion of patients who suffered an adverse event or if a medical decision was made to terminate treatment due to poor response. Lost to follow up was defined as the proportion of patients that interrupted DR-TB treatment for two or more consecutive months for any reason.

To minimize potential errors, included articles and the SRDR data extraction template were reviewed repeatedly. When uncertainty arose with deciding the inclusion of studies, opinion of experts implementing DR-TB programs in Nigeria were sought. This only occurred twice throughout the duration of the study.

Assessment of risk of bias within and across included studies {#Sec5}
-------------------------------------------------------------

Since studies were observational, the methodological quality of each study was determined using the Newcastle-Ottawa Quality Assessment Scale (NOS) scale and the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement \[[@CR20], [@CR21]\]. In the NOS scale, a maximum of nine points is assigned to cohort studies and eight points to case control. Studies are assigned points for measurement of exposure and outcomes, and selection of participants. Studies with NOS score \< 4 were deemed low quality, 4--5 as moderate quality, and ≥ 6 as high quality. Furthermore, the risk of bias across studies was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. Studies were classified as low (observational study), and very low (any other evidence). According to Higgins and Green \[[@CR22]\], definitions of GRADE of evidence include;High: Further research is very unlikely to change confidence in the estimate of effectModerate: Further research is likely to have an important impact on the confidence in the estimate of effect and may change the estimateLow: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimateVery low quality: We are very uncertain about the estimate

Furthermore, the Cochrane Collaboration's handbook was used to assess whether certain steps were taken to reduce the risk of bias under six domains \[[@CR23]\]. Domains include allocation concealment, blinding, incomplete outcome data, and sequence generation, selective outcome reporting and other sources of bias. Judgment was categorized as yes (low risk of bias) and no (high risk of bias) or unclear.

Data synthesis and analysis {#Sec6}
---------------------------

Using a random effects model, a one-arm meta-analysis was conducted using Open Meta-Analyst (OMA) software to analyze and record data from the included studies \[[@CR24]\]. Due to the nature of data from eligible studies (i.e. cases without controls or comparison groups), a one-arm meta-analysis was suitable. Thus, the odds ratio could not be used to estimate the strength of association rather the use of proportion was suitable. Meta-analysis was performed by analyzing separately and comparing studies classified as community based and hospitalization that reported outcomes on treatment success and treatment failure.

Data are presented graphically using the forest plot, in which the proportion, its 95 % CI, and the overall summary statistic was estimated \[[@CR25]\]. Under the assumption of the random effects model, estimates of tau square (tau^2^), Q statistic, and I square statistic (I^2^) were generated and used to evaluate heterogeneity \[[@CR25]\]. An I^2^ value of 50 % or greater and where *P* \< 0.05 was used to denote high heterogeneity \[[@CR26]\]. Meta-regression analysis was conducted to assess whether effect estimates differed by patient age, adverse effect, default rate, and treatment duration, thus explaining any of the heterogeneity in the study \[[@CR25], [@CR27]\]. The dependent variable was DR-TB success rate and all 9 studies that implemented community-based treatment were included. The analysis was based on a significance at alpha 0.05 level.

Sensitivity analysis using trim and fill was conducted to further explain the heterogeneity observed \[[@CR28]\]. The potential for publication bias was considered by assessing a visual inspection of the funnel plot symmetry, Begg's regression, and Egger linear regression test. Additionally, subgroup analysis was conducted to investigate heterogeneity and determine if outcomes differ on several study and intervention characteristics. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was adhered to in this review \[[@CR29]\].

Results {#Sec7}
=======

Our search identified a total of 89 publications, of which 21 were duplicates (Fig. [1](#Fig1){ref-type="fig"}). Of the 68 articles screened, 23 articles were not eligible and excluded. Full text of 45 articles was reviewed, of which 29 articles were excluded due to the following reasons: qualitative study design, meta-analysis review, mode of treatment, and desired outcomes not reported. One study was not found because it was not available on CRD as at the time of the search. In total 16 studies from 9 MDR-TB HBC (Bangladesh, China, Ethiopia, Kenya, India, South Africa, Philippines, Russia, and Uzbekistan) met the inclusion criteria for this study.

Study characteristics {#Sec8}
---------------------

Table [1](#Tab1){ref-type="table"} shows the summary characteristics of the 16 studies included in the meta-analysis. Nine studies \[[@CR6], [@CR11], [@CR14], [@CR30]--[@CR35]\] implemented a community-based intervention while seven studies \[[@CR36]--[@CR42]\] implemented traditional hospitalization. The sample size for each category of patients includes: XDR-TB (29), MDR-TB & XDR-TB (807) and MDR-TB (2508). Twelve studies \[[@CR6], [@CR11], [@CR14], [@CR31], [@CR33]--[@CR36], [@CR39]--[@CR42]\] included MDR-TB patients, three studies \[[@CR30], [@CR32], [@CR37]\] had both MDR and XDR TB patients, and one study \[[@CR38]\] included only XDR-TB patients.Table 1Summary of Findings: Community-based treatment compared with traditional hospitalization for MDR-TB and XDR-TB patientsAuthor, Year, Country of Study, Study periodArm, N, Percent Female, AgeIntervention ComponentsIntervention setting, Intervention provider, Length of DOTSDrug model, number of drugs, treatment duration (intensive, continuation phase), Proportion previously treatedBrust JC 2012 \[[@CR12]\]\
Prospective cohort\
South Africa\
2008--2010Community-based intervention *N* = 80 Female: 63 %\
Age: 34 HIV+: 83 %Extensive training of PHC staff, Routine home visits, Clinician support, DOTS supervised by healthcare worker, DOTS supervised by family treatment supporter, DOTS supervised by a healthcare worker, Education of patients and family treatment supporter, Adherence support and adverse event monitoring, Mobile multidisciplinary teams of home care providers & HIV treatmentDecentralized, outpatient\
Friends/relatives staying close by, Home care support, DOTS nurse, Community Health Extension Worker (CHEW)\
Throughout therapyStandardized 6, NR 6, 24 NRBrust JC 2010 \[[@CR39]\]\
Retrospective cohort\
South Africa\
2000--2003Traditional hospitalization *N* = 1209 Female: 39 %\
Age: 33 HIV+: 52 %HospitalizationHospital\
No DOTS provider\
Partial ObservationStandardized\
5,4 4-6, 18 NRCox H 2007 \[[@CR41]\]\
Retrospective cohort\
Uzbekistan\
2003--2005Traditional Hospitalization\
*N* = 87\
Female: 39.1 %\
Age: 31\
HIV+: NRHospitalizationHospital\
Trained facility based healthcare worker\
NRIndividualized\
6, NR 6,18 100 %Cox H 2014 \[[@CR30]\]\
Retrospective cohort\
South Africa\
2005--2011Community-based intervention *N* = 1208 Female: 50 %\
Age: 33 HIV+: 70 %Extensive training of primary health care center (PHC) staff, Routine home visits, Clinician support, Social assistance and support groups, DOTS^a^ supervised by healthcare workerPHC\
Trained facility based healthcare worker\
Throughout therapyStandardized 5, NR ^b^\
6, 18 NRHirpa S 2013 \[[@CR42]\]\
Case control study\
Ethiopia\
2011--2012Traditional Hospitalization\
*N* = 134\
Female: 39.5 %\
Age: 25.1\
HIV+: 13.4 %Clinician support\
Healthcare workersHospital\
Trained facility based healthcare worker\
Partial observationStandardized\
5, NR\
NR, NR\
NR, NRJoseph P 2011 \[[@CR33]\]\
Prospective cohort\
India\
2006--2007Community-based intervention *N* = 38 Female: 34.2 %\
Age: NR HIV+: NRExtensive training of PHC center staff, Routine home visits, education of patients and family treatment supporter, Supply of drugs to local health centerNR\
Trained facility based healthcare worker, Friends/relatives staying close by, Private medical practitioners\
Throughout therapyStandardized\
6,4 6--9, 18 NRKeshavjee S 2008 \[[@CR38]\]\
Retrospective cohort\
Russia\
2000--2004Traditional Hospitalization\
*N* = 608 Female: NR\
Age: 33.9 HIV+: NRHospitalization and DOTS supervised by healthcare workerHospital\
DOTS supervised by healthcare worker\
Partial ObservationIndividualized 5, 5\
6--9, 18 100 %Liu CH 2011 \[[@CR37]\]\
Retrospective cohort\
China\
1996--2009Traditional Hospitalization\
*N* = 576 Female: 33.9 %\
Age: 41 HIV+: NRClinician supportHospital\
NR\
NRIndividualized 5, NR ^c^\
18, 18 68.7 %Vaghela JF 2015 \[[@CR14]\]\
Prospective cohort\
India\
2009--2012Community-based intervention *N* = 101 Female: 40.6 %\
Age: 33 HIV+: NRExtensive training of primary health care center staff, Physical and mental support Counseling, Routine home visits, Adherence support and adverse event monitoring, Mobile multidisciplinary teams of home care providers, Vocational rehabilitation, Hygiene & Nutrition counseling, Nursing care, Financial rehabilitationPHC, Patient home\
Trained facility based healthcare worker, Home care support\
Throughout therapyNR NR, NR 6, 24--27 NROyieng'o D 2012 \[[@CR11]\]\
Retrospective cohort\
Kenya\
2008--2010Community-based intervention *N* = 14 Female: 50 %\
Age: NR HIV+: 50 %Extensive training of PHC staff, Routine home visits, Clinician support, DOTS supervised by family treatment supporter, DOTS supervised by healthcare worker, Education of patients and family treatment supporter, Adherence support and adverse event monitoring, Mobile multidisciplinary teams of home care providersDecentralized, Local Health Centre\
Friends/relatives staying close by, Home care support, DOTS nurse, CHEW\
Throughout therapyStandardized\
5,4 6, 18 NRSingla R 2009 \[[@CR34]\]\
Retrospective cohort\
India\
2002--2006Community-based intervention *N* = 126 Female: 42 %\
Age: 26 HIV+: NRDOTS supervised by family treatment supporter, Daily supervised treatment in peripheral health centers, decentralized careDecentralized\
Friends and family staying close by\
Throughout therapyStandardized\
5,3 6--9, 18 NRShin SS 2007 \[[@CR40]\]\
Retrospective cohort\
Russia\
2000--2002Traditional Hospitalization\
*N* = 244 Female: 9.2 %\
Age: 31 HIV+: NRHospitalization and trained facility based healthcare workerTrained facility based healthcare worker\
Throughout therapyIndividualized NR, NR\
18.5, 18 100 %Tupasi TE 2006 \[[@CR31]\]\
Retrospective cohort\
Philippines\
1999--2002Community-based intervention *N* = 117 Female: 26 %\
Age: 38 HIV+: NRDOTS supervised by healthcare worker, Daily supervised treatment in peripheral health centers, Home based DOTSPHC, Patient home\
Trained facility based healthcare worker\
Partial ObservationIndividualized\
NR, NR 6, 18 18.8 %Thomas A 2007 \[[@CR32]\]\
Prospective cohort\
India\
1999--2003Community-based intervention *N* = 66 Female: 30.3 %\
Age: 38 HIV+: NRRoutine home visits, Clinician support, DOTS supervised by healthcare worker, Financial rehabilitationPHC, Patient home\
Trained facility based healthcare worker, Village health worker, private provider\
Partial ObservationIndividualized\
5,NR 6--9, 12 100 %Van Deun A 2010 \[[@CR36]\]\
Prospective cohort\
Bangladesh\
1997--2007Traditional hospitalization *N* = 427 Female: 25.5 %\
Age: 31.7 HIV+: NRClinician supportHospital\
Trained facility based healthcare worker\
NRStandardized\
NR, NR NR, NR 100 %Wei X 2015 \[[@CR35]\]\
Retrospective cohort\
Ethiopia\
2990--2102Community- based intervention\
N: 110\
Female: 26.4 %\
HIV+: Yes (NR)Routine home visits, DOTS supervised by healthcare worker and familyPHC, Patient home\
Village health worker, family\
Throughout therapyStandardized\
5, NR 6, 18 NR^a^DOTS, Directly observed therapy short course^b^ *NR* Not reported^c^ *NR* Not reported

Eight studies \[[@CR30]--[@CR32], [@CR36], [@CR38], [@CR40]--[@CR42]\] utilized healthcare workers, two studies \[[@CR6], [@CR11]\] utilized a combination of home care support teams and families, two studies \[[@CR33], [@CR35]\] used both healthcare workers and family, and one study each used home care support teams (14) and family \[[@CR34]\] as a DOTS-Plus provider. For treatment of DR-TB patients, nine studies \[[@CR6], [@CR11], [@CR30], [@CR31], [@CR33]--[@CR36], [@CR39], [@CR42]\] utilized standardized treatment and six used individualized regimen \[[@CR31], [@CR32], [@CR37], [@CR38], [@CR40], [@CR41]\]. Treatment duration for the intensive and continuous phase ranged from 4 to 6 months and 12--27 months. Eleven studies \[[@CR11], [@CR30]--[@CR32], [@CR34], [@CR35], [@CR37]--[@CR39], [@CR42]\] used at least five drugs and two studies \[[@CR6], [@CR33]\] used six drugs in their treatment regimen. In addition, DOTS-Plus was observed throughout therapy in 9 studies \[[@CR6], [@CR11], [@CR14], [@CR30], [@CR33]--[@CR36], [@CR40]\] and five studies \[[@CR31], [@CR32], [@CR38], [@CR39], [@CR42]\] reported partial observation.

Assessment of risk of bias in individual studies {#Sec9}
------------------------------------------------

Table [2](#Tab2){ref-type="table"} provides a detailed overview of items evaluated against each study using the NOS statement, STROBE, GRADE methodology, and Cochrane domains to assess the risk of bias within and across studies. Six studies \[[@CR36]--[@CR40], [@CR42]\] were evaluated as having low quality and the rest of the studies have very low quality. Only four studies \[[@CR6], [@CR40]--[@CR42]\] had incomplete outcome data and six studies \[[@CR6], [@CR31], [@CR33], [@CR35], [@CR41], [@CR42]\] have selective outcome reporting.Table 2Assessment of risk of bias within and across included studiesStudyStudy yearNOS/ STROBE scoreGRADEAllocation concealment (Selection bias)BlindingIncomplete outcome dataRandom sequence generationSelective outcome reportingOther sources of biasCox H20144/19VLNYYNYABrust JC20124/19VLNYNNNA, DVaghela JF20154/19VLNYYNYA, DOyieng'o D20124/19VLNYYNNA, DJoseph P20114/19VLNYYNNA, DVan Deun A20105/20LNYYNYA, DBrust JC20105/20LNYYNYA, DSingla R20094/19VLNYYNYA, DTupasi TE20064/19VLNYYNYA, DThomas A20074/19VLNYYNYA, DLiu CH20115/20LNYYNYA, DKeshavjee S20085/20LNYYNYA, DShin SS20075/19LNYNNYA, DCox HS20074/19VLNYNNNA,DWei XL20154/19VLNYYNNA,DHirpa S20135/20LNYNNNA, DA Attrition bias, D Detection biasVL Very Low: We are very uncertain about the estimateL Low: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimateH High: Further research is very unlikely to change our confidence in the estimate of effectNOS score \< 4: Low qualityNOS score 4--5: Moderate qualityY: Low risk of biasN: High risk of bias

Results of individual studies {#Sec10}
-----------------------------

In Fig. [2](#Fig2){ref-type="fig"}, five studies \[[@CR11], [@CR30]--[@CR32], [@CR35]\] implementing community-based treatment had treatment success rate less than the overall summary estimate of 67.8 % and four studies \[[@CR37]--[@CR39], [@CR42]\] utilizing traditional hospitalization had treatment success rate less than the overall treatment success rate of 56.9 %. The p value for heterogeneity was \<0.001, with I^2^ = 85.60 %, indicating a significant heterogeneity among studies. Four studies \[[@CR31]--[@CR33]\] reported treatment failure rates higher than the overall summary estimate of 6.5 % for community-based studies and 3 studies \[[@CR37], [@CR38], [@CR42]\] utilizing traditional hospitalization had treatment failure rates above its overall estimate of 18.8 %, with significant heterogeneity (*p* = \<0.001, I^2^ = 97.24 %).Fig. 2Pooled treatment success rate (cured and treatment completed) of MDR-TB and XDR-TB community-based intervention versus traditional hospitalization. The pooled treatment success rate for community-based studies (**a**) is higher than studies that utilized the traditional hospitalization (**b**) for treatment of MDR-TB and XDR-TB cases

Synthesis of results {#Sec11}
--------------------

Pooled estimates of treatment success and failure rates were calculated as shown in Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"} for community-based treatment and traditional hospitalization. The pooled probability of being cured and completing treatment using a community-based treatment is 67.8 % (95 % CI: 0.593 to 0.762) compared with traditional hospitalization at 56.9 % (95 % CI: 0.44.3 to 0.695). All studies equally contributed to the heterogeneity of the pooled estimate; thus, there was no need to investigate studies contributing to the heterogeneity.Fig. 3Pooled treatment failure rate of MDR-TB and XDR-TB community-based intervention versus traditional hospitalization. The pooled treatment failure rate for community-based (**a**) is lower than that of traditional hospitalization (**b**)

Figure [3](#Fig3){ref-type="fig"} shows the meta-analysis of treatment failure rate for community-based treatment and traditional hospitalization. The probability of MDR-TB and XDR-TB patients failing treatment in community-based treatment is 6.5 % (95 % CI: 0.03 to 0.10; *p* \< 0.01) compared to traditional hospitalization at 18.8 % (95 % CI: 0.10 to 0.28; *p* \< 0.01). There is an extremely high amount of heterogeneity of treatment failure for community-based treatment (I^2^ = 71.90 %, *p* \< 0.001) and traditional hospitalization (I^2^ = 97.24 %, *p* \< 0.001), where a high level of heterogeneity of I^2^ \> 50 % is considered to be substantial \[[@CR43]\].

Subgroup analysis {#Sec12}
-----------------

Since an extremely high heterogeneity was observed, subgroup analysis of study and intervention characteristics was conducted and presented in Table [3](#Tab3){ref-type="table"}. Studies without HIV co-infected \[[@CR14], [@CR30], [@CR33]--[@CR35]\] patients (72 %, 95 % CI: 0.65 to 0.79) reported higher treatment success rate than studies with HIV co-infected \[[@CR6], [@CR11], [@CR30], [@CR32], [@CR35], [@CR37]--[@CR40], [@CR42]\] patients (57 %, 95 % CI: 0.49 to 0.64). In addition, the 95 % CI for studies with these characteristics: duration of DOTS-plus, length of treatment, and number of drugs in regimen were non-overlapping indicating a statistically significantly relationship with treatment success. However, the 95 % CI overlapped for drug regimen model, DOTS-plus location, DOTS-plus provider, patient type, type of treated patients, adverse events, quality of studies, and start year of studies, thus, indicating studies with these characteristics are not significantly different.Table 3Results from sub group analysis on treatment successVariables\# of StudiesPoint Estimate95 % CIStart year of study 2000 or later \[[@CR6], [@CR11], [@CR14], [@CR30], [@CR33]--[@CR35], [@CR38]--[@CR42]\]120.640.540.74 1999 or earlier \[[@CR31], [@CR32], [@CR36], [@CR37]\]40.600.440.77Quality of study Very Low \[[@CR6], [@CR11], [@CR14], [@CR30]--[@CR35], [@CR39], [@CR41]\]110.650.540.75 Low \[[@CR36]--[@CR38], [@CR40], [@CR42]\]50.590.440.74Adverse Events  \< 50 % \[[@CR34]--[@CR36]\]30.760.700.82  \> 50 % \[[@CR6], [@CR31]--[@CR33], [@CR38], [@CR40]--[@CR42]\]80.630.520.73Type of treated patients New cases and previously treated \[[@CR6], [@CR30]--[@CR32], [@CR34]--[@CR37], [@CR39], [@CR41], [@CR42]\]110.610.520.71 Previously treated patients \[[@CR11], [@CR33], [@CR38], [@CR40]\]40.660.530.78HIV co-infected patients^a^ Yes \[[@CR6], [@CR11], [@CR30], [@CR32], [@CR35], [@CR37]--[@CR40], [@CR42]\]100.570.490.64 No \[[@CR14], [@CR30], [@CR33]--[@CR35]\]60.720.650.79Patient type MDR \[[@CR6], [@CR11], [@CR14], [@CR31], [@CR33]--[@CR36], [@CR39]--[@CR42]\]120.670.560.78 MDR and XDR \[[@CR30], [@CR32], [@CR37]\]30.510.480.55 XDR \[[@CR38]\]10.480.300.66DOTS-plus Provider Healthcare workers \[[@CR30]--[@CR32], [@CR36], [@CR38], [@CR40]--[@CR42]\]80.590.480.69 Home care support teams & Family \[[@CR6], [@CR11]\]20.780.600.95 Home care support teams \[[@CR14]\]10.710.620.80 Healthcare workers & Family \[[@CR33], [@CR35]\]20.720.610.83 Family \[[@CR34]\]10.790.720.86Drug Regimen Model Standardized \[[@CR6], [@CR11], [@CR30], [@CR33]--[@CR36], [@CR39], [@CR42]\]90.660.530.79 Individualized \[[@CR31], [@CR32], [@CR37], [@CR38], [@CR40], [@CR41]\]60.570.510.62DOTS-plus Location Health center \[[@CR14], [@CR30], [@CR33], [@CR34]\]40.700.560.84 Patient home \[[@CR6]\]10.840.760.92 Patient home and Health center \[[@CR11], [@CR31], [@CR32], [@CR35]\]40.610.530.68 Hospital \[[@CR36]--[@CR42]\]70.570.440.69Duration of DOTS-plus^a^ Throughout therapy \[[@CR6], [@CR11], [@CR14], [@CR30], [@CR33]--[@CR36], [@CR40]\]90.720.650.79 Partial observation \[[@CR31], [@CR32], [@CR38], [@CR39], [@CR42]\]50.500.430.57Length of treatment (months)^a^  \< 18 \[[@CR32], [@CR42]\]20.480.420.55 18 & above \[[@CR6], [@CR11], [@CR14], [@CR30]--[@CR35], [@CR37], [@CR39]--[@CR41]\]120.650.560.74Drugs in regimen^a^ 5 \[[@CR11], [@CR30]--[@CR32], [@CR34], [@CR35], [@CR37]--[@CR39], [@CR41], [@CR42]\]110.570.490.64  \> 5 \[[@CR6], [@CR33]\]20.820.760.89^a^Non-overlapping 95 % CI

Meta-regression analysis {#Sec13}
------------------------

Table [4](#Tab4){ref-type="table"} shows the results from meta-regression analysis on continuous covariates that are independently associated with outcomes. For community-based studies, results suggest that as age of patients' increases, treatment success rates of patients' decreases by 3.1 % (β:-0.031, 95 % CI:-0.044 to -0.019, *p* \< 0.001). We found a significant interaction between treatment success and lost to follow up (β:0.009, 95 % CI:0.005 to 0.014, *p* \< 0.001). Furthermore, an increase in treatment length moderated an increase in treatment success rate (β:0.020, 95%CI:0.007 to 0.033, *p* \< 0.01).Table 4Meta regression analysis of included in studies implementing community-based treatmentVariablesCoefficients95 % CIP-valueAge−0.031−0.044−0.019\<0.001Lost to follow up0.0090.0050.014\<0.001Adverse rate0.0050.0030.006\<0.001Treatment length0.0200.0070.0330.003Omnibus p value: 0.000

Sensitivity analysis and publication bias {#Sec14}
-----------------------------------------

We found conflicting results between Egger's and Begg's test. Egger's test indicated asymmetrical distribution (intercept = 4.04, 95 % CI: 0.791 to 7.290, *p* = 0.018) while Begg's adjusted rank correlation test (*p* = 0.192) did not show evidence of publication bias. A sensitivity analysis was conducted by repeating the meta-analysis using the trim and fill method to assess the effect of studies on the overall pooled estimate. In the trim and fill method, no missing study was trimmed (Point estimate = 0.634, 95 % CI: 0.557 to 0.705) (Fig. [4](#Fig4){ref-type="fig"}). Figure [4](#Fig4){ref-type="fig"} shows funnel plot asymmetry arising from heterogeneity that is due entirely to their being distinct subgroups of studies, each with a different intervention effect. For studies implementing traditional hospitalization, one study was trimmed (Point estimate = 0.599, 95 % CI: 0.472 to 0.615) while no study was trimmed for community-based interventions (Point estimate = 0.681, 95 % CI: 0.593 to 0.685) (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Illustration of funnel plot asymmetry due to heterogeneity. The figure shows the Funnel plot of standard error by logit event rate for all studies (**a**), community based studies (**b**), and hospital based studies (**c**)

Discussion {#Sec15}
==========

Summary of evidence {#Sec16}
-------------------

This review combined data from 16 observational studies from 9 MDR-TB HBC. Across these studies, the overall sample size was 3344 MDR-TB and XDR-TB patients receiving second line anti-TB drugs. We compared the effect of community-based treatment with traditional hospitalization in improving treatment success rates among MDR-TB and XDR-TB patients in the 27 MDR-TB HBC. Our findings suggest that community-based treatment improved treatment success rate than traditional hospitalization methods.

All the studies reported outcomes on treatment success rate. According to the WHO Global Tuberculosis Report of 2015, only three MDR-TB high burden countries (Estonia, Ethiopia, and Myanmar) achieved a treatment success rate of ≥ 75 %, which equals the overall estimate in our study \[[@CR1]\]. The study by Brust \[[@CR12]\] reported the highest treatment success rate (84 %) using community-based treatment. However, with a very low quality of evidence and small sample size (*n* = 80), were having much confidence in the result may be debatable. Amongst the seven studies that implemented a traditional hospitalization method, treatment success rate ranged from 43.5 % \[[@CR39]\] to 78.2 % \[[@CR36]\].

Across the included studies, the pooled treatment failure estimate ranged from 6.5 % and 18.8 % for community-based and traditional hospitalization respectively. Treatment failure rates were generally lower in community-based treatments compared to traditional hospitalization treatments. We observed extremely low treatment failure rates in studies by Singla \[[@CR34]\] and Brust \[[@CR12]\] at 3 % and the failure rate in Keshavjee \[[@CR38]\] at 31 % \[[@CR6], [@CR34], [@CR38]\]. Our findings show a lower estimate than that obtained from the Global Tuberculosis Report \[[@CR1]\] where 10 % of XDR-TB patients in 40 countries for whom outcomes were reported failed treatment.

Furthermore, we found that studies with significant patient and treatment characteristics significantly influenced treatment success rate. In the meta-regression model of treatment success, age, adverse rate and lost to follow up could possibly explain the extremely high heterogeneity observed, although, inferences from statistical heterogeneity may be uncertain.

Since there is a considerable high amount of heterogeneity (\>75 %) between the study populations and varying sampling methods, there is a low confidence that this is the true population effect or that there even is a meaningful single effect. Statistical heterogeneity may arise because of clinical differences between studies (i.e. setting, types of participants, or implementation of the intervention) or methodological differences \[[@CR44]\]. The extremely high heterogeneity observed from treatment outcomes studied could be as a result of combining studies with a mix of intervention components or controlling for different confounders. In addition, a plausible explanation to the high heterogeneity could be the diverse characteristics in the study settings. Despite an extensive search, studies from other HBC were not located. Likewise, differences in methodological quality may also cause heterogeneity and lead to funnel plot asymmetry. Smaller studies tend to be conducted and analyzed with less methodological rigor than larger studies \[[@CR44]\].

Agreements and disagreements with other studies or reviews {#Sec17}
----------------------------------------------------------

Treatment outcomes among patients with MDR-TB have been previously assessed \[[@CR19], [@CR45]--[@CR47]\]. Two studies \[[@CR5], [@CR16]\] compared the effectiveness of centralized versus decentralized MDR-TB treatment. The treatment success rate (68 %) in this review is slightly higher than the estimate reported in the latest systematic review published in 2014, which showed a treatment success rate of 65 % in community-based treatments \[[@CR19]\]. Furthermore, our result is slightly higher than that obtained from an individual study by Loveday et. al which obtained a treatment success rate of 58 % using community-based treatment \[[@CR15]\].

Overall, we observed a higher treatment success rate in patients treated with standardized drug regimen than individualized drug regimen, however, this was not significantly different. Our findings are similar to that reported by Weiss \[[@CR19]\]. On the contrary, a review by Orenstein \[[@CR48]\] reported higher treatment success rate in patients treated with individualized regimen than standardized regimen. Furthermore, studies with duration of treatment \> 18 months reported a higher treatment success rate than studies \< 18 months of treatment. Our finding is similar to that from WHO guidelines for the programmatic management of DR-TB where patients previously treated with MDR regimen for a total duration of \> 24 months were more successful than \<24 months \[[@CR47]\]. Although, we focused our analysis on the continuation phase, however, we found that treatment success rate was significantly higher when treatment duration was 18 months and above.

Limitations {#Sec18}
-----------

There are several limitations to this study. First, the pooled results of estimates may not be generalizable to all the 27 MDR-TB HBC as only 9 countries are represented in our review. Additionally, these pooled rates may not represent all MDR-TB and XDR-TB patients in sampled countries where only small sample sized studies have been done. Secondly, eligible studies utilized before and after study design, which significantly reduced the quality of our results and limited the comparability of findings. Furthermore, among the included studies, not all desired outcomes reported time points of treatment outcomes, thus limiting analysis to studies with available information.

Although, our meta-regression analysis explained heterogeneity, community-based treatment is a multifactorial intervention and other factors could interfere with treatment success, treatment failure, and high heterogeneity. Thus, the possibility of residual heterogeneity may exist \[[@CR27]\] and it cannot be ascertained whether variables included in the model are sources of bias. The number of covariates was limited to avoid the problem of multiplicity and false-positive results \[[@CR26]\]. However, despite these limitations it appears that community-based treatment significantly improved treatment success rates in DR-TB patients.

Conclusion {#Sec19}
==========

The pooled estimate for treatment outcomes in our study indicates extremely high heterogeneity among studies, which is statistically significant. The evidence indicated that treatment success was significant among subgroups with certain study and treatment characteristics.

Implications for practice {#Sec20}
-------------------------

In this review, we examined the effects of subgroups and meta-regression on treatment outcomes. In view of the limited data on MDR-TB and XDR-TB from other MDR-TB HBC, we have identified community-based treatment to improve treatment outcomes in MDR-TB and XDR-TB patients. Our findings here further strengthen the need for decentralizing MDR-TB treatment, integrating patient centered care, and financing for TB treatment to expand community-based treatment interventions. Community-based treatment can be tailored to suit diverse settings as well as patient and treatment characteristics. Thus, TB program managers should explore implementing community-based treatment rather than traditional hospitalization in MDR-TB and XDR-TB patients.

Implications for research {#Sec21}
-------------------------

Due to poor quality of included studies, well-designed studies are needed to further establish the impact of community-based management on TB treatment outcomes. Specifically, future studies should measure and report time points of data collection on treatment outcomes and detailed description of intervention components.
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